150 MG Trastuzumab For Injection

150 MG Trastuzumab For Injection Specification

Indication
Breast Cancer, Gastric Cancer (HER2 Positive)

Origin
India

Salt Composition
Trastuzumab 150 mg

Dosage Form
Tablet

Enzyme Types
Trastuzumab For Injection

Feature
Humanized Monoclonal Antibody, Targeted Therapy

Application
Intravenous Administration

Ph Level
5.8 - 6.3 (reconstituted solution)

Physical Color/Texture
White to Off-White Lyophilized Powder

Fermentation Smell
Odorless

Storage Instructions
Cool & Dry Place

Shelf Life
24 Months

Precautions
Administer under supervision of qualified physician; monitor for infusion-related reactions

Administration Route
Intravenous (IV) infusion only

Marketed By
Various pharmaceutical manufacturers

Reconstitution Volume
7.2 ml (to achieve a final concentration of 21 mg/ml)

Inactive Ingredients
L-histidine, L-histidine hydrochloride, trehalose, polysorbate 20

Product Type
Parenteral Cancer Therapy

Disposal Instructions
Dispose unused product and waste material in accordance with local regulations

Suitable For
Adults

Compatibility
Should not be mixed or diluted with other drugs except as recommended

ATC Code
L01XC03

Diluent Provided
Yes, sterile water for injection

Prescription/Non Prescription
Prescription Only

Pack Type
Single-use glass vial with sterile water for injection for reconstitution

Strength
150 mg/vial

150 MG Trastuzumab For Injection Trade Information

Minimum Order Quantity
5000 Pieces

Supply Ability
100 Pieces Per Day

Delivery Time
3-4 Days

Main Export Market(s)
Asia, Australia, Central America, North America, South America, Eastern Europe, Western Europe, Middle East, Africa

Main Domestic Market
All India

About 150 MG Trastuzumab For Injection

150 MG Trastuzumab For Injection supplied under the tradename Hetraz is meant for I.V. infusion. The vial can be used multiple times. This prescription medicine has Trastuzumab as an active ingredient that is used in the treatment of different kinds of cancer, like breast and stomach. Oncologists can prescribe this medicine alone or along with other anticancer drugs based on the treatment and other factors. 150 MG Trastuzumab For Injection can cause certain side effects, like nausea, stomach upset, lack of sleep, weight loss, tingling and numbness of hands and feet, sore throat, mouth ulcers, etc.

Targeted Therapy for HER2-Positive Cancers

Trastuzumab for Injection 150 mg is developed as a targeted therapy specifically for adults diagnosed with HER2-positive breast or gastric cancers. By binding directly to the HER2 receptor on cancer cells, it disrupts cell growth pathways, offering a precise and effective treatment. Its robust efficacy has made it a critical choice in oncology settings globally.

Easy Reconstitution and Administration Guidelines

Supplied in a single-use glass vial with sterile water for injection as diluent, the product is reconstituted using 7.2 ml to achieve a 21 mg/ml solution suitable for intravenous infusion. Healthcare professionals must ensure the product is not mixed with other drugs unless specified and administer the infusion in a clinical environment, carefully monitoring for possible infusion reactions.

Safe Handling and Storage Recommendations

Trastuzumab for Injection should be stored in a cool, dry place and used within its 24-month shelf life. Proper handling includes preparing the infusion under aseptic conditions and disposing of unused material and waste according to local safety and environmental protocols. This ensures optimal safety for both patients and healthcare staff.

FAQ's of 150 MG Trastuzumab For Injection:

Q: How should Trastuzumab 150 mg for Injection be prepared and administered?

A: Trastuzumab 150 mg for Injection should be reconstituted with 7.2 ml of sterile water for injection to achieve a 21 mg/ml concentration. After gentle mixing, the solution is administered only through intravenous infusion under the supervision of a qualified physician.

Q: What conditions is this medication used to treat?

A: This product is used for the treatment of HER2-positive breast cancer and gastric cancer in adults, as confirmed by appropriate diagnostic testing.

Q: When should Trastuzumab for Injection not be mixed with other drugs?

A: Trastuzumab should not be mixed or diluted with other drugs except as recommended in prescribing information, as incompatibilities may reduce its efficacy or safety.

Q: Where should the unused product and waste material be disposed of?

A: Any unused product and waste material must be disposed of safely in accordance with local regulatory requirements and institutional protocols to prevent environmental contamination.

Q: What benefit does Trastuzumab offer for cancer patients?

A: Trastuzumab targets the HER2 receptor present on cancer cells, inhibiting their growth and improving clinical response rates, thus offering a significant advancement in the treatment of HER2-positive cancers.

Q: How should the product be stored before use?

A: The product should be stored in a cool and dry place, protected from light and moisture, and used within its 24-month shelf life for maximum effectiveness.